Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yeah , sure but that being said it doesn't figure that you would not research the management of this Team and family member Avtar Dillion who just plead guilty to the SEC x 3 counts .
especially with your impressive Resume' .....
You got something to say to someone why don't you say something meaningful don't breathe?
Out here I'm trying to make some risk liquidity and some investment and avoid dilution should that be done as any part of investing son?
FWIW: SBI-100's pre-clinical trial data showed stronger and longer-lasting reduction in IOP compared to Xalatan/Latanoprost, already giving it the edge in terms of efficacy. If it's found to also offer neuroprotection that would make it clearly superior to its competitors. (See https://www.biospace.com/article/releases/skye-bioscience-reports-potential-neuroprotective-benefit-of-sbi-100-in-preclinical-glaucoma-model/)
I can't answer the market share / reinvention questions; they're above my pay grade. GLTA!
WTF? ......I only made it up to ILLliterate .
There are currently no less than 5 prescription medications available for IOP disorder , the most commonly prescribed would be Xalatan . if Skye got SBI-100 all the way through FDA approval , Why would this product be superior ?
and ....thus prescribed more so than the widely known Xalatan ?
what kind of market share $$$ are we talking to re-invent the wheel ?
TIA.....
That I in paid for it to gain with the company and value to my position how does it not make sense son what's the demand here what are you trying to alliterate?
NEWS: Skye Bioscience to Present at RHK 2022 Disruptive Growth Conference
https://www.newsfilecorp.com/release/145231
This post makes no sense
Taking in ask no in excuse longs? this could go major dollars meeting fiduciary judicatory "REQUIREMENTS INTERESTS in longs on way pay the fortunate?
News: Skye Bioscience Submits Investigational New Drug Application for SBI-100 Ophthalmic Emulsion to FDA
https://www.newsfilecorp.com/release/144594
NEWS: Skye Bioscience Initiates First-in-Human Phase 1 Clinical Trial for SBI-100
https://www.newsfilecorp.com/release/144472
Skye Bioscience Stockholders Vote in Favor of Arrangement Agreement with Emerald Health Therapeutics, Inc.
https://ir.skyebioscience.com/news-events/press-releases/detail/143/skye-bioscience-stockholders-vote-in-favor-of-arrangement
NEWS: Skye Bioscience Completes Drug Production for Phase 1 Clinical Study
https://ceo.ca/@GlobeNewswire/skye-bioscience-completes-drug-production-for-phase
NEWS: Skye Bioscience Files Definitive Proxy Statement and Announces Stockholder Meeting Date
https://ceo.ca/@GlobeNewswire/skye-bioscience-files-definitive-proxy-statement-and
NEWS OUT: Emerald Health Therapeutics Receives Court Approval of Plan of Arrangement with Skye Bioscience
https://ceo.ca/@newsfile/emerald-health-therapeutics-receives-court-approval
These guys are full of it. Shareholders speak and they dont listen. Just another example of the scam. Cant stand this company(s) BS.
All anyone has to do is look at the chart and the current criminal proceeding to realize EMHTF is crooked.
News: Emerald Health Therapeutics, Inc. Provides Update on and Additional Background to Transaction with Skye Bioscience
https://ceo.ca/@newsfile/emerald-health-therapeutics-inc-provides-update-on
Cant say I blame the shareholders. EMHTF is trash (ran by a Dhillon) and their is the brother Punit Dhillon running this one so not sure shareholder guidance will be heeded
BRIEF-Shareholders Oppose Plan Of Arrangement Between Emerald Health Therapeutics And Skye Biosciences Inc
6:06am ET, 08/04/2022 - Reuters
Aug 4 (Reuters) - Emerald Health Therapeutics Inc:
* GROUP OF SHAREHOLDERS OPPOSE PLAN OF ARRANGEMENT BETWEEN EMERALD HEALTH THERAPEUTICS AND SKYE BIOSCIENCES INC.
* OPPOSING SHAREHOLDERS OF EMERALD HEALTH THERAPEUTICS SAY THEY OPPOSE ANNOUNCED PLAN OF ARRANGEMENT BETWEEN EMERALD AND SKYE BIOSCIENCES INC Source text for Eikon: Further company coverage:
Skye Bioscience Updates Phase 1 Timeline.
https://www.stocktitan.net/news/SKYE/skye-bioscience-updates-phase-1-rq325hooer12.html
Wow! Talk about at the buzzer. They hit their Q2 approval goal.
Let's see if we can execute on the timeline for starting the trial + interim data this year, then final data in Q1 next year!
(From their corporate presentation):
SBI-100 OE: PHASE 1
? Q1-22: Completion of GLP toxicology studies
? Q2-22: AUS Human Research Ethics Committee (HREC) approval to start Phase 1 study
? Q3-22: Phase 1 interim data
? Q1-23: Phase 1 final data
Long-awaited HREC approval FINALLY lands. Phase 1 human trials set to start!
https://www.newsfilecorp.com/release/129574/Skye-Bioscience-Receives-Australian-Ethics-Committee-Approval-to-Start-FirstinHuman-Phase-1-Study-of-SBI100-Ophthalmic-Emulsion?src=stocktwits
Our CEO Punit Dhillon will be presenting at an investor Zoom call today for shareholders and investors at 4:30pm ET . They are also presenting to institutional investors at the HC Wainwright conference next week. Exciting times for this company. I'm hoping for developments in the near term. Looking forward to getting an update on the call today!! Register hear to attend:
https://www.eventbrite.com/e/skye-bioscience-inc-webinar-5192022-registration-341385472137?utm_source=eventbrite&utm_medium=email&utm_content=follow_notification&utm_campaign=following_published_event&utm_term=Skye+Bioscience%2C+Inc.-Webinar+5%2F19%2F2022&aff=ebemoffollowpublishemail
Emerald already owes 25% of Skye,
https://whalewisdom.com/stock/lglrd
NEWS OUT...
Skye Bioscience hires CMAX to run its phase 1 study of lead candidate SBI-100 OE for glaucoma
https://ca.proactiveinvestors.com/companies/news/980839?SNAPI
Skye just filed a 10-K with 83 sections and 10 exhibits. Check it out!
https://last10k.com/sec-filings/skye/0001516551-22-000004.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=10KQ2040F&utm_term=skye
Skye Bioscience Reports Positive Results for SBI-100 in GLP Toxicology Study
https://ceo.ca/@nasdaq/skye-bioscience-reports-positive-results-for-sbi-100
Who else is adding right now? I've been able to average down to $.06
That's what most of the long holders think. Covid delayed a lot with the Australian trials.
this guy said they were going in the clinic and they completed a preIND w FDA. that's significant step fwd if anything materializes. that was a milestone for past 3years on their presentations if they actually moved past this step with the cash they claim to have on hand this this thing could move to phase 2 fairly quickly...could it be???
so quiet here
Skye Bioscience (SKYE) -
Please register to attend SKYE's Zoom presentation next week with Punit Dhillon, CEO. There will be a quick review of the PPT with live Q&A at the conclusion. The network is intended for Accredited Investors and shareholders.
Please register using this link:
https://www.amazon.com/dp/B01N9FXMW5?tag=drawnacom-20&linkCode=osi&th=1&psc=1&dn_platform=website
We should start moving in december...finaly
Is it just me or is chart looking a lot like last 2 breakouts above .20
no i did not.. i sold at 0.07
this hit almost 0.04 today
Good luck here
You sold and took a loss on the low.. Bold move
sold and took a loss here.
I was an investor with Nemus and become one when Skye was created
but now 500 million outstanding?
before it was under 200million
Dilution is a killer.
good luck
Skye recently updated its clinical development strategy and timeline for its Phase I study, focused on safety and tolerability in 48 healthy volunteers, which is being initiated in Q2-22 in Australia.
I'll believe it when I see it. I've seen this data when they were NMUS, then when they were EMBI, now SKYE has managed to regurgitate the same useless press release. This isn't some new company this is same bag of crap it was 3 names ago. Another Dhillon dumpster fire...outstanding
Skye Bioscience Sponsored Research Presented at American Association of Pharmaceutical Scientists Meeting PharmSci 360
https://www.globenewswire.com/news-release/2021/10/21/2318363/0/en/Skye-Bioscience-Sponsored-Research-Presented-at-American-Association-of-Pharmaceutical-Scientists-Meeting-PharmSci-360.html
Yep when Company starts issuing shares to fund operations I'm out i sold... Seen this dog and pony show too many times...
Followers
|
138
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6315
|
Created
|
11/12/14
|
Type
|
Free
|
Moderators |
Our lead candidate, THCVHS, a proprietary prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT).
Previous US government studies in humans discovered that THC was able to reduce intraocular pressure (IOP), which is in part responsible for the crush-like injury to the cells of the optic nerve that can eventually result in blindness. Additional preclinical studies have shown the potential for THC to also provide neuroprotective benefit, which may be especially important to patients with glaucoma who are experiencing disease progression with normal IOP levels.
One of the major drawbacks of previous studies of the use of THC for glaucoma was that they relied on inhalation or ingestion of THC. These systemic routes of drug administration cause negative side effects like psychotropic effects and potentially decreasing blood pressure , which resulted in the American Academy of Opthamology determining that the adverse effects of systemic cannabis administration/consumption outweighed its therapeutic benefit.
At Skye Bioscience, we chemically modify THC to create a unique synthetic molecule with the intent to safely realize the known positive effects of THC. Our molecule enables enhanced local delivery in the eye, reduced systemic side effects, and the potential for neuroprotection for the treatment of ocular diseases.
Glaucoma is a group of eye diseases that can cause vision loss and blindness by damaging a nerve in the back of the eye called the optic nerve. Damage to the optic nerve is caused by increased intraocular pressure (IOP) due to improper drainage and/or overproduction of fluid in the eye.
According to the American Academy of Ophthalmology, glaucoma affects over 75million people worldwide and is the leading cause of blindness in adults aged 60 and older.
Current therapies can lower IOP but progressive tolerance requires switching or combining drugs. They do NOT provide neuroprotective capabilities.
In preclinical studies, Skye’s THCVHS demonstrated the potential to significantly reduce intraocular pressure (IOP) – exceeding the capabilities of leading commercialized drugs in the current glaucoma market.
Additionally, it has been demonstrated:
We develop novel and proprietary classes of synthetic molecules through the modification of naturally derived systems.
Shifting the solutions paradigm on a effective treatment of diseases through the development of novel neuroprotective solutions.
Science First
The foundation of Skye Bioscience.
Revolutionary Solutions
Solving unmet needs of diseases with limited treatment offerings.
Product-led
Commercial differentiated applications to provide therapeutic benefits.
Impact driven
Change makers. Platform solutions that can extend beyond a single disease.
Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors.
Mr. Diep brings more than 15 years of scientific and clinical research experience to Skye Bioscience. Prior to joining Skye, Mr. Diep was at Protox Therapeutics Inc.
Richard has more than 30 years of business experience and served as a Vice President to CFO on multiple companies in a wide range of industries both public and private, domestic and international.
Mr. Kim serves as the General Counsel and Director of IP at Emerald Bioscience. He is an experienced biotech executive and corporate attorney, and a registered patent attorney.
Karam Takhar serves as Vice President, Corporate Development & Investor Relations at Skye Bioscience Inc. Prior to joining Skye, Mr. Takhar was at Emerald Health Sciences.
Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors.
Mr. Heppell is the co-founder, President and Director of BC Advantage Funds (VCC) Ltd., a venture fund that invests in and builds technology, life science and clean technology companies.
Dr. Dalesandro is the President of Brecon Pharma Consulting, a full-service biotech consultancy firm focused on identifying and obtaining critical information early in product development.
Dr. Muñoz is a Professor of Immunology in the Department of Cell Biology, Physiology, and Immunology of the University of Córdoba, Spain.
Dr. Pasquale is a Professor of Organic Chemistry, Department of Pharmaceutical Sciences at the University of Eastern Piedmont, Novara, Italy, where his research activities focus on isolation ..
Dr. Goldberg is the Professor and Chair of Ophthalmology and Director of the Spencer Center for Vision Research at the Byers Eye Institute at Stanford University.
Dr. Pasquale is the Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai in New York City.
Dr. Ritch holds the Shelley and Steven Einhorn Distinguished Chair in Ophthalmology and is Clinical Professor of Ophthalmology at the Mt. Sinai Medical School and Surgeon Director Emeritus.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |